[go: up one dir, main page]

WO2012022120A8 - Dihydropyrazole compounds - Google Patents

Dihydropyrazole compounds Download PDF

Info

Publication number
WO2012022120A8
WO2012022120A8 PCT/CN2011/001378 CN2011001378W WO2012022120A8 WO 2012022120 A8 WO2012022120 A8 WO 2012022120A8 CN 2011001378 W CN2011001378 W CN 2011001378W WO 2012022120 A8 WO2012022120 A8 WO 2012022120A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
dihydropyrazole
formula
dihydropyrazole compounds
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2011/001378
Other languages
French (fr)
Chinese (zh)
Other versions
WO2012022120A1 (en
Inventor
张艳
陈俊宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KBP Biosciences Co Ltd
Original Assignee
KBP Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KBP Biosciences Co Ltd filed Critical KBP Biosciences Co Ltd
Priority to CN201180031781.5A priority Critical patent/CN103052632B/en
Publication of WO2012022120A1 publication Critical patent/WO2012022120A1/en
Anticipated expiration legal-status Critical
Publication of WO2012022120A8 publication Critical patent/WO2012022120A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are a dihydropyrazole compound as represented by general formula (Ia), a pharmaceutically acceptable salt or isomer thereof, a preparation process thereof, a pharmaceutical preparation containing such compounds and the use thereof. The definitions of the various substituents in formula (Ia) are as described in the specification. The compounds can be used for treating and/or preventing renal injury, cardiovascular diseases, especially hypertension, and/or endocrine diseases.
PCT/CN2011/001378 2010-08-18 2011-08-18 Dihydropyrazole compounds Ceased WO2012022120A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201180031781.5A CN103052632B (en) 2010-08-18 2011-08-18 Dihydropyrazole Compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201010256527 2010-08-18
CN201010256527.2 2010-08-18
CN201010549656 2010-11-12
CN201010549656.0 2010-11-12
CN201110080789 2011-03-23
CN201110080789.2 2011-03-23

Publications (2)

Publication Number Publication Date
WO2012022120A1 WO2012022120A1 (en) 2012-02-23
WO2012022120A8 true WO2012022120A8 (en) 2013-02-21

Family

ID=45604725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001378 Ceased WO2012022120A1 (en) 2010-08-18 2011-08-18 Dihydropyrazole compounds

Country Status (2)

Country Link
CN (1) CN103052632B (en)
WO (1) WO2012022120A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362095B1 (en) 2015-10-13 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
ES2973248T3 (en) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Mineralocorticoid receptor antagonist for the treatment of osteoarthritis
WO2021180818A1 (en) 2020-03-11 2021-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008020113A1 (en) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
DE102006050513A1 (en) * 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia
DE102006050515A1 (en) * 2006-10-26 2008-04-30 Bayer Healthcare Ag New substituted dipyridiyl-dihydropyrazolone derivatives are hypoxia-inducible transcription factor-prolyl-4-hydroxylase inhibitors useful to treat/prevent e.g. cardiovascular diseases, heart-circulation diseases, heart failure and anemia

Also Published As

Publication number Publication date
CN103052632B (en) 2014-03-19
WO2012022120A1 (en) 2012-02-23
CN103052632A (en) 2013-04-17

Similar Documents

Publication Publication Date Title
IN2014KN00948A (en)
WO2012019426A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
WO2012019430A8 (en) Phthalazinone derivative, and preparation method and pharmaceutical use thereof
UA109868C2 (en) N -alkyltriazole compounds asr
WO2013100566A8 (en) Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
WO2012118308A3 (en) Composition for preventing and treating cardiovascular diseases, containing pyrazole derivative
WO2012122340A8 (en) Soluble guanylate cyclase activators
BR112012026767A2 (en) compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, method for treating or preventing disorders, and use of a compound or salt
MD20140072A2 (en) New pyrrole compounds, process for their preparation and pharmaceutical compositions containing them
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
HRP20191617T1 (en) Combination comprising an mek inhibitor and a b-raf inhibitor
WO2013004995A8 (en) Pyrimidinone compounds and their use
TN2012000248A1 (en) Novel spiropiperidine compounds
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
HK1255500A1 (en) Oxysterols and methods of use thereof
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
ZA201802312B (en) A group of compounds used for the treatment or prevention of hyperuricemia or gout
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
WO2009140341A3 (en) Atorvastatin compositions
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2014036502A8 (en) Tetracycline compounds
EA201291014A1 (en) TRICYCLIC INDUSAL COMPOUND, METHOD FOR ITS OBTAINING AND CONTAINING IT PHARMACEUTICAL COMPOSITION
MX2014003701A (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180031781.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817648

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11817648

Country of ref document: EP

Kind code of ref document: A1